Leading quantitative analyst Vahan Janjigian looks to American Oriental Bioengineering (NYSE: AOB), a maker of Chinese traditional medicines, among his latest featured stocks.

In his The Forbes Growth Investor, the advisor explains, "This market has enjoyed significant growth over the past several years due to several favorable trends." Here's his review.

"American Oriental Bioengineering is a pharmaceutical company that specializes in manufacturing and marketing plant-based traditional Chinese medicines (TCM) in China.

"Plant-based pharmaceuticals (PBP),which generated 82% of Q1 sales, are medicinal compounds derived from the leaves and roots of plants. These products, which are approved by the Chinese State Food and Drug Administration (SFDA), are used to treat various illnesses.

"The Chinese pharmaceutical market has enjoyed significant growth over the past several years due to several favorable trends.

Continue reading American Oriental (AOB): Forbes quant eyes Chinese medicine

American Oriental (AOB): Forbes quant eyes Chinese medicine originally appeared on BloggingStocks on Wed, 10 Sep 2008 11:30:00 EST. Please see our terms for use of feeds.